Articles published by CytoDyn Inc.
March 2025 Letter to Shareholders
March 18, 2025
December 2024 Letter to Shareholders
December 17, 2024
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
November 04, 2024
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
October 04, 2024
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
September 24, 2024
September 2024 Letter to Shareholders
September 09, 2024
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
August 23, 2024
CytoDyn to Host Webcast to Provide Company Update
May 28, 2024
May 2024 Letter to Shareholders
May 16, 2024
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
November 2023 Letter to Shareholders
November 03, 2023
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022